ABIONYX Pharma Announces the Completion of a Contribution in Kind to the Company of 100% of the Capital of IRIS Pharma Holding, Fully Compensated by the Issue of New Shares at a Price of €3.60 Per Share to Become a Specialist of Bioproducts...
- IRIS Pharma becomes a subsidiary of ABIONYX Pharma and remains independent in its service activities for major pharmaceutical and biotech companies in the ophthalmology sector
- A potential portfolio of 3 new biologic product candidates that could enter into the clinical phase in 14 potential indications in ophthalmology
TOULOUSE, France--(BUSINESS WIRE)--
ABIONYX Pharma Announces the Completion of a Contribution in Kind to the Company of 100% of the Capital of IRIS Pharma Holding, Fully Compensated by the Issue of New Shares at a Price of €3.60 Per Share to Become a Specialist of Bioproducts in Ophthalmology and Renal Indications
ABIONYX Pharma (FR0012616852 – ABNX – PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today announces the final completion of a contribution in kind to the company of 100% of the capital of IRIS Pharma Holding, who owns 100% of Iris Pharma, one of the leaders specialized in preclinical and clinical contract research services in the field of ophthalmology. The transaction was fully remunerated by the issuance of new ABIONYX Pharma shares at a price set at 3.60 euros per share. The completion of the contribution in kind follows a successful capital increase in cash via a private placement for an amount of 4.2 million euros at a price of 3.60 euros per share.
About IRIS Pharma
IRIS Pharma is a French company, one of the world leaders in preclinical and clinical research in the field of ophthalmology. Founded in 1989 by Dr. Pierre-Paul ELENA and managed today by Yann QUENTRIC, IRIS Pharma has been providing services in the development of ophthalmic drugs and ocular medical devices to pharmaceutical industries, biotechnology companies and research institutes worldwide (Europe, North America, Asia) for more than 30 years. Having participated in the development of more than 70 ocular drugs and medical devices currently on the international market, IRIS Pharma is recognized as one of the world's leading experts in the ophthalmic community.
About ABIONYX Pharma
ABIONYX Pharma is a new generation biotech company that aims to contribute to health through innovative therapies in indications where there is no effective or existing treatment, even the rarest ones. Thanks to its partners in research, medicine, biopharmaceuticals and shareholding, the company innovates on a daily basis to propose drugs for the treatment of renal and ophthalmological diseases, or new HDL vectors used for targeted drug delivery.
+33 (0)1 44 71 98 53
+33 (0)1 44 71 00 15